Five highlights of the pharmaceutical industry in 2017
Release time:
2020-08-14
2017 NPC and CPPCC Five Major Points in Pharmaceutical Industry
3# September 3 , 2017 NPC and CPPCC will be held in Beijing. The issues and decisions of the NPC and CPPCC will directly affect the overall trends and trends of the industry in the following year and have a profound impact on the future economy and major assets. The following is a summary of the highlights of 5 in the pharmaceutical industry during the 2017 NPC and CPPCC sessions.
1 , Supply-side Reform: Value Chain Distribution Faces Reconstruction
The so-called supply-side reform is to promote the development of economic industry by liberating productivity from the supply and production sides. As early as last year's Spring Festival, the State Council meeting focused on the pharmaceutical industry and proposed measures such as "aiming at the urgent needs of the masses, improving the safety evaluation and product traceability system, combining the" three medical "linkage reform, and building a pharmaceutical circulation network throughout the township", hoping to promote the innovation and upgrading of the pharmaceutical industry through supply-side reform. From
to this year, the health planning Commission held a press conference on 2 8 , saying that through the implementation of the "action plan to further improve medical services", the service process has been continuously optimized, the medical quality has been continuously improved, the service mode has been continuously innovated, and the doctor-patient relationship has been continuously harmonious. 2017 The Health Planning Commission and the State Administration of Traditional Chinese Medicine have identified 11 key tasks to further improve medical services, including expanding the real-name appointment diagnosis and treatment pilot.
In addition, the General Office of the State Council issued a blockbuster document entitled "Several Opinions on Further Reforming and Improving Drug Production, Circulation and Use Policies" on 2 January 9 , which aroused strong repercussions in the pharmaceutical industry. The "opinion" points out that starting from the three major links of drug production, circulation and use is an important reform document covering the entire pharmaceutical industry chain, which will play a key role in further promoting the supply-side structural reform of the pharmaceutical industry. it will also have a far-reaching impact on the future healthy development of the pharmaceutical industry.
If 2016 is the year of supply-side reform, then 2017 will be the year of deepening the supply-side reform of medical reform. Supply-side structural reform has become the key word of this year's "two sessions" medicine.
2 , medical reform: the formation of a basic medical and health system framework
medical reform has always been a hot issue of concern. the key work points of 2017 published by the health planning Commission proposed that the medical reform should be continuously deepened and the formation of a basic medical and health system framework should be accelerated. These include measures such as promoting the hierarchical diagnosis and treatment system, accelerating the establishment of a modern hospital management system, and implementing the reform of the drug supply guarantee system. In addition, medical reform has also been mentioned in the government work reports of the local two sessions that have been implemented, and various localities have "bright moves" to solve the problem of people seeing a doctor ".
Zhejiang Province has achieved "double sinking and two upgrading" of medical resources through the establishment of a medical consortium, alleviating the current situation of people's difficulty in seeing a doctor, and accelerating the reform of "Internet + medical prices.
medical reform has always been one of the key reform projects promoted by the State Council. Deepening the reform of the medical and health system and strengthening the construction of the medical service system will become the focus of attention and heated discussion among the representatives of the two sessions.
3 , medical and nursing integration: make up for shortcomings and solve the pension problem
With the increasing aging of the population, new requirements have been put forward for the development of medical care. In the "Several Opinions on Accelerating the Development of Elderly Care Services" issued by the State Council in 2013 , it was proposed to "promote the integrated development of medical care and elderly care", which pointed out the direction for the development of my country's elderly care industry. This year, Zhejiang proposed to actively promote the reform of the old-age insurance system, study and formulate a linkage adjustment mechanism for the basic pension for retirees and the minimum standard of basic pension for urban and rural residents, and steadily raise the standards of basic pension and basic pension.
At the National Two Sessions, elderly care has become an issue of high concern, and the quality of life of the elderly in their later years will affect the stability of the entire society. How to improve the quality of elderly care services has received special attention.
4
, Pollution Control: Hundreds of pharmaceutical companies may face suspension of production. Environmental protection has always been a topic of close attention throughout the country. According to the data of the legal network voting system, as of 2017
2 April 28 , smog control ranked among the top 10 hot spots of the NPC and CPPCC with 19598 votes. 2017 is the second year of the 13th Five-Year Plan and a key year for environmental protection. Last year in the middle and late of December 1, there was a large-scale continuous severe air pollution in our country. Satellite monitoring shows that the scope of smog was once expanded to 17
provinces, autonomous regions and municipalities in, covering an area of 142 .09 million square kilometers, that is to say, more than 1/7 of the country was shrouded in smog. With such a "power" of the haze, naturally become the focus of attention of the various provinces. It is no longer news to use ten "haze" volts to describe the weather in Beijing-Tianjin-Hebei region during winter heating. However, after the Spring Festival this year, the "Beijing-Tianjin-Hebei and Surrounding Areas Air Pollution Prevention and Control Work Plan for 2017
(Draft for Comments ) " ( hereinafter referred to as "Plan" ) once again pushed pharmaceutical companies in the region to the forefront. If this "plan" becomes a reality, hundreds of pharmaceutical enterprises in "2+26 " cities such as Beijing, Tianjin, Shijiazhuang, Jinan, Zhengzhou and Taiyuan will not be allowed to produce for 120 days throughout the year. According to the implementation promotion plan of ( Ten Atmospheric Articles
)issued by the State Council in 2013 , 2017 is the final assessment year of the action plan. Environmental protection has naturally become one of the hot words of the two sessions this year.
, Reform of State-owned Enterprises: Mixed Reform of Pharmaceutical Enterprises Station in UpportSince 2016
, various regions have successively issued a number of special supporting documents to implement the "Guiding Opinions on Deepening the Reform of State-owned Enterprises" promulgated and implemented by the CPC Central Committee and the State Council, and the "four beams and eight pillars" of the reform of state-owned enterprises have risen, accelerate from "design" to "construction".1 Since September, the local two sessions have been intensively held, and the reform of state-owned enterprises has once again become the focus of the local "two sessions. 2016
# Decemberth June 29 , Yunnan Baiyao controlling shareholder Baiyao Holdings introduced about 254 billion yuan to Xinhuadu Industrial Group Co., Ltd. through capital increase. Baiyao Holding's equity structure was changed to Yunnan SASAC and Xinhuadu each holding 50% equity. At present, the company's core business consists of the provincial pharmaceutical company, the pharmaceutical division, the health products division and the traditional Chinese medicine resources division, which are respectively responsible for the four major business sectors of pharmaceuticals, health daily chemical products, traditional Chinese medicine resources products and pharmaceutical commerce. The initial completion of the mixed reform plan of Baiyao Holdings has made Yunnan Baiyao a model of performance growth in the pharmaceutical industry. Since the listing of in 1993 , Yunnan Baiyao has led its peers in performance growth. Compared with listed companies under state-owned enterprises in Yunnan Province, Yunnan Baiyao's return on net assets and other indicators are also far ahead. In the report on accelerating the reform of state-owned enterprises recently released by the Tianjin State-owned Assets Supervision and Administration Commission, the timetable and roadmap for Tianjin Pharmaceutical Group Co., Ltd. to promote the reform of state-owned enterprises clearly emerged. Among them, increasing the intensity of mixed reform, using the listing platform to achieve asset securitization and improving the assessment and incentive mechanism have become the three highlights. Some pharmaceutical industry analysts pointed out that from the perspective of the reform route, Tianyao Group has continued the overall thinking of the current state-owned enterprise reform. It is another typical case of initiating the reform of state-owned enterprises in the pharmaceutical industry after Yunnan Baiyao.
pharmaceutical enterprise reform results show, the company's profitability and overall value has been further improved. On the basis that the top-level design of the reform of state-owned enterprises has been basically completed, the reform of pharmaceutical state-owned enterprises will gradually reach a climax in 2017
, which will affect the future direction of pharmaceutical investment to a certain extent. (article from the network)
More information
Pharmaceutical Company Established New Drug R & D Promotion Committee
Recently, the new drug research and development promotion committee of Jianfeng pharmaceutical company was formally established, which will be responsible for promoting the new drug research and development progress of pharmaceutical companies and subordinate enterprises, and coordinating the new drug research and development work of various departments and subordinate enterprises. The New Drug Promotion Committee is headed by Huang Jinlong, deputy general manager of the group and general manager of the pharmaceutical company, and Jiang Hong, deputy general manager of the pharmaceutical company, is headed by Pang Xiong, Shi Cunyuan, Xu Lizhen, Yu Jingjing, Zheng Kunwu, Feng Lixiang, Kang Litao, Li Qian, Wu Chonggui, Zhai Tsunami, Huang Fang and Tong Xiaojun. The committee has an office, and Shi Cunyuan is also the director of the office, responsible for the supervision, communication, and coordination of the company's new drug research and development projects. The main responsibilities of the new drug promotion committee include: organizing the establishment and improvement of the R & D project management system and relevant regulations of the pharmaceutical company; organizing the formulation of the development plan of the new drug R & D project of the pharmaceutical company and supervising the implementation; making decisions on project initiation and participating in project evaluation; supervising the management of new drug R & D of the pharmaceutical company and providing guidance; Responsible for the process management of new drug R & D projects and the promotion and coordination of new drug R & D; carry out the assessment of new drug research and development projects; issue the responsibility system assessment and task statement of new drug research and development projects; be responsible for solving major technical problems in the process of new drug research and development; be responsible for the research and improvement of the management mode of research and development projects of pharmaceutical companies; be responsible for the future trend analysis of new drug research and development projects; review the major scientific research achievements of pharmaceutical companies and put forward reward suggestions. Huang Jinlong said that the research and development of new drugs is an important foundation for the healthy development of the pharmaceutical industry and is a systematic project. Jianfeng Pharmaceutical has always attached great importance to the research and development of new drugs, but there is still a certain gap between the progress of research and development and the development process of the enterprise, and the lack of coordination in the research and development process also affects the progress and quality of new drug research and development to a certain extent. The purpose of the establishment of the New Drug Research and Development Promotion Committee is to solve the progress of new drug research and development, to find and solve problems in time, to implement more targeted, and to effectively integrate enterprise resources, improve the speed and quality of new drug research and development, and make good product reserves for the healthy development of pharmaceutical companies. (Reporter Ni Yingzhen)
2020
09-11
Jianfeng Pharmaceutical ranks among the top 100 Chinese pharmaceutical industries in 2019
On August 25, the "2019 Top 100 Series List of China's Pharmaceutical Industry" was released in Kunming. Zhejiang Jianfeng Pharmaceutical Company was shortlisted as one of the top 100 enterprises in China's pharmaceutical industry. The product Berunning (Olopatadine Hydrochloride Eye Drops) was selected as the "Most Growing Product Brand" of China's pharmaceutical industry ". The "Top 100 Pharmaceutical Industry Series List" was evaluated and released by Guangzhou Punctuation Pharmaceutical Information Co., Ltd., a subsidiary of the Southern Institute of Pharmaceutical Economics of the State Drug Administration, and is known as the "Oscar in Chinese Pharmaceutical Industry. Southern Institute is the earliest institution in China that specializes in pharmaceutical industry policy and market economy research, pharmaceutical market research, pharmaceutical economic data analysis and research, and pharmaceutical professional media publishing. It is in the field of market information value-added services and media communication and marketing services in China's pharmaceutical and health industry., The field of professional quality improvement has extremely extensive influence. The "Top 100 Pharmaceutical Industry" is comprehensively evaluated by the company's annual pharmaceutical industry sales revenue, total profit and R & D investment results. On the same day, the "most growing product brand" of Chinese medicine selected by the Southern Institute's media "Pharmaceutical Economic News" was released simultaneously. Spike Pharmaceuticals product Beirunning (Olopatadine Hydrochloride Eye Drops) was selected. (Xu Yuting)
2020
09-01
Company Disclosure 2020 Semi-Annual Report
On August 28, the Group held the 16th meeting of the 10th Board of Directors of the Company by means of communication, and considered and adopted the "2020 Semi-Annual Report of Jianfeng Group" and the "Proposal on Changes in the Company's Accounting Policy". On August 29, the Company's 2020 semi-annual report was publicly disclosed on the Shanghai Stock Exchange and the Shanghai Securities News and China Securities News. In the first half of the year, the Group focused on the general policy of "grasping projects, making up for shortcomings, improving quality and efficiency, and constantly improving the core competitive advantage", and on the basis of doing a good job in epidemic prevention and control, the Group seized the resumption of work and production, accelerated project construction, and enhanced the core competitiveness of enterprises. In the first half of 2020, the company achieved total operating income of 1.44 billion yuan, net profit attributable to shareholders of 0.368 billion yuan, net profit per share of 1.07 yuan. As of the end of June 2020, the Company's total assets were $5.892 billion, net assets were $4.068 billion, and net assets per share were $11.82. From February to April, affected by the epidemic, the national project construction progress slowed down, cement market demand decreased; after May, the epidemic was effectively controlled, infrastructure investment continued to recover, the real estate industry continued to pick up, cement sales steadily rebounded. During the outbreak, Daye Peak completed the technical transformation projects such as the cold machine, cement mill, into the desulfurization tower anti-corrosion transformation, to ensure the efficient operation of the production equipment after the resumption of work. Yunnan peak rotary kiln production, cement production and other major technical and economic indicators of steady rise; comply with market trends, timely adjustment of marketing policies. Guizhou Jianfeng has promoted the project infrastructure construction, equipment installation and commissioning, raw material bidding and other work in an orderly manner, and through preliminary publicity to enhance the popularity of the Jianfeng brand in the local area, and make a series of preparations for the transformation from project construction to production and operation. In the first half of 2020, the reform of China's medical and health system continued to deepen, and new policies were introduced intensively. Peak Pharmaceuticals and its subsidiaries in the epidemic prevention work at the same time in the first time to achieve the resumption of production, and actively organize donations to support the fight against the epidemic, was named the annual "war epidemic star" the most socially responsible pharmaceutical enterprises. In the first half of the year, Jianfeng Pharmaceutical continued to increase the introduction and development of varieties, and JFAN-1001 applied for clinical application of new anti-tumor drugs. At present, it has obtained the notice of approval for clinical trials. Optimize the production process of API workshop and further shorten the production cycle of raw materials. Continue to improve product sales policies and strengthen market channel control. Shanghai North Carolina further straightened out the internal management structure, production and marketing convergence more smoothly, continue to promote the construction of Anhui North Carolina and Anhui Zhongwang Phase II technical transformation project, promote the peak pharmaceutical raw materials, preparations integration of industrial upgrading strategy. Other business segments of the company actively responded to the challenge of the new crown epidemic and carried out production and operation activities in a standardized and orderly manner. Tianjin natural products company vigorously explore the international and domestic markets, sales revenue to achieve steady growth. Peak Health focuses on the basic idea of "sales orientation, burden reduction and efficiency improvement, fine-grained savings, cost reduction and efficiency enhancement" to effectively improve the operational efficiency of enterprises. Jianfeng International Trade has actively developed new storage business varieties and achieved practical results, and has become the first enterprise in Jinhua to formally obtain the qualification of "network freight. Peak cable seizes the special needs of communication cables such as subways, vigorously promotes large logarithmic cables for subways, and strives to achieve the long tail effect. On the same day, the company also held the 10th meeting of the Ninth Board of Supervisors and reviewed and approved relevant reports. (residual fruit)
2020
09-01
The company organizes new employee induction training
From August 12 to 14, in order to strengthen the training of talents in the group and improve the comprehensive quality of new employees, Jiang Xiaomeng, secretary of the party committee and chairman of the group company, Yu Jianhong, general manager, and other leaders and heads of relevant enterprises and departments conducted a three-day induction training for new employees. New employees from foreign enterprises such as Guizhou Huangping Peak, Daye Peak and Shanghai North Carolina participated simultaneously through online methods. In the course of corporate culture, General Manager Yu Jianhong started from the history of the development and struggle of the peak, divided into five stages: hard work, determined reform, diversified development, strategic adjustment, and strategic development, and introduced in detail the development process of the group company and the current industrial layout., The results achieved; from the aspects of enterprise spirit, vision, development philosophy, values, business philosophy, etc, this paper introduces the peak corporate culture rooted in 62 years of history and inherited in the blood; from the perspective of an enterprise manager and old employees, he speaks a lot of truth to the new employees and puts forward a lot of hopes and suggestions. Chairman Jiang Xiaomeng took "How New Employees Achieve Win-Win with Enterprises" as the topic, and proposed that the key to the success of an enterprise lies in how to select, retain, educate and employ people. Peak and employees complement each other. Peak can achieve today's achievements and the struggle of generations of peak people are inseparable. He also taught new employees the basic concepts that need to be understood, the basic qualities that need to be possessed and the sense of hardship in entering the new environment through 16 key words, and combined with his own experience and quoting from others, he analyzed the core elements of success, the signs of a successful career, the personal qualities that need to be possessed for success, and the importance of establishing a personal knowledge management system, it expresses the ardent hope of new employees to adjust their mentality, keep learning, clear goals, clear dreams, cultivate win-win thinking, and grow up together with the peak. The heads of the human resources department of the group company, the safety management office of the group company, and the comprehensive department of the pharmaceutical company also taught the new employees the corporate rules and regulations and the "Employee Handbook", safety knowledge and professional ethics. The new employees also visited the group exhibition hall and had a deeper understanding of the development history and enterprise achievements of the peak. After the training, the human resources department also organized an examination to test the training effect. (Reporter Chen Shengmu)
2020
08-21
According to this newspaper, through the interconnection monitoring of the transportation department in Zhejiang province, the network freight platform of peak international trading company passed the online service capability audit, interface access audit, eight capability identification and other audit procedures, and successfully obtained the road transportation business license with the qualification of "network freight" on July 2. It is understood that Jianfeng International Trade is currently the first enterprise in Jinhua and Quzhou to obtain this qualification.
2020
08-05
News from our newspaper On July 21, Xi Jinping, General Secretary of the Central Committee of the Communist Party of China, President of the State, and Chairman of the Central Military Commission hosted a symposium for entrepreneurs in Beijing and delivered an important speech. Over the past few days, the General Secretary's speech has aroused strong repercussions in all walks of life. On July 23, Jiang Xiaomeng, chairman of the group company, said in an interview with Jinhua TV that the general secretary's speech was calm and inspiring, and pointed out the direction of future work for entrepreneurs.
2020
08-05
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page